Polarean Imaging PLC NDA Submission (2996B)
07 Octubre 2020 - 1:00AM
UK Regulatory
TIDMPOLX
RNS Number : 2996B
Polarean Imaging PLC
07 October 2020
Polarean Imaging Plc
("Polarean" or the "Company")
NDA Submission
NDA submission for Polarean's hyperpolarised (129) Xenon gas
drug-device diagnostic for lung imaging
Polarean Imaging plc (AIM: POLX), the medical--imaging
technology company, with an investigational drug--device
combination product for magnetic resonance imaging (MRI), announces
its submission of a New Drug Application ("NDA") and request for
priority review to the US Food and Drug Administration ("FDA") for
hyperpolarised (129) Xenon gas used to evaluate pulmonary function
and to visualise the lung using MRI.
The submission of the NDA follows the Company's successful
completion of two Phase III clinical trials (the "Clinical Trials")
which demonstrated effective measurement of regional lung
ventilation. In the Clinical Trials, Polarean's (129) Xenon gas MRI
was used to measure regional pulmonary function in patients with a
wide variety of underlying lung diseases who were being evaluated
for possible lung resection or lung transplant surgery. As detailed
in the Company's announcement of 29 January 2020, both Clinical
Trials met their primary endpoints, showing pre-defined equivalence
of hyperpolarised (129) Xenon Gas MRI to an approved comparator,
(133) Xenon Scintigraphy, and displayed a benign safety
profile.
(129) Xenon, when polarised in Polarean's proprietary
drug-device system, permits functional, regional and quantitative
imaging of the lungs using MRI, without the risk of exposing
patients to ionising radiation. The polarised (129) Xenon is
administered as an inhaled gas that is given to patients in a 10
second breath-hold MRI procedure.
Commenting on the submission, Richard Hullihen, CEO of Polarean,
said: "The NDA submission of (129) Xenon gas MRI as a drug-device
combination represents another key regulatory milestone for our
Company. I am delighted with the performance of Polarean's team,
who have worked tirelessly to achieve this important goal, and
would also like to thank the institutions, clinicians and patients
who took part in the studies that have formed part of this NDA.
"More than 30 million Americans suffer from a chronic lung
disease and we see a significant unmet need for non-invasive,
quantitative and cost-effective image-based diagnostic technology
without exposing patients to ionising radiation. W e look forward
to working with the FDA to address this unmet need."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Contacts:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Jonathan Allis, Chairman
SP Angel Corporate Finance LLP Nomad Tel: +44 (0)20 3470 0470
and Broker
David Hignell / Soltan Tagiev (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7876
741 001
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, medical drug-device
combination companies operating in the high-resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation.(129) Xe gas is currently
being studied for visualisation of gas exchange regionally in the
smallest airways of the lungs, the tissue barrier between the lung,
and the bloodstream and in the pulmonary vasculature. Xenon gas
exhibits solubility and signal properties that enable it to be
imaged within other tissues and organs.
The Group also develops and manufactures high performance MRI
radiofrequency (RF) coils which are a required component for
imaging (129) Xe in the MRI system. The development of these coils
by the Group facilitates the adoption of the Xenon technology by
providing application-specific RF coils which optimize the imaging
of (129) Xe in MRI equipment for use as a medical diagnostic as
well as a method of monitoring the efficacy of therapeutic
intervention.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFVTIILRIII
(END) Dow Jones Newswires
October 07, 2020 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024